サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1262039

肺がん治療薬市場-世界の産業規模、シェア、動向、機会、予測、2018-2028年がん細胞タイプ別（非小細胞肺がん、小細胞肺がん）、治療別、地域別にセグメント化

Lung Cancer Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Cancer Cell Type (Non-small Cell Lung Cancer, Small Cell Lung Cancer ), By Treatment, By Region
出版日: | 発行: TechSci Research | ページ情報: 英文 116 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

肺がん治療薬市場-世界の産業規模、シェア、動向、機会、予測、2018-2028年がん細胞タイプ別（非小細胞肺がん、小細胞肺がん）、治療別、地域別にセグメント化
出版日: 2023年04月01日
発行: TechSci Research
ページ情報: 英文 116 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の肺がん治療薬市場は、予測期間中に目覚ましい成長を遂げると予測されています。

市場成長の要因は、肺がんの発生率の増加と肺がんに関連する高度な治療法です。

肺がんの有病率の増加

肺がん（小細胞がん、非小細胞がんとも）は、世界的に見ても2番目に多いがんです。米国がん協会による2022年の肺がんの推計では、米国で約23万6740人（男性11万7910人、女性11万8830人）の肺がん患者が新たに報告され、約13万180人（男性6万8820人、女性6万130人）が肺がんが原因で死亡しました。さらに、生涯の期間における男性の肺がん有病率は全体で15分の1、女性では17分の1程度とされています。この数字には、喫煙者と非喫煙者が含まれています。

免疫療法の需要の高まり

免疫系の自然な防御機能を刺激し、がんに対抗できるようにする薬物療法、ワクチン療法、その他の治療法は、免疫療法として知られています。抗PD-1」と呼ばれる免疫療法薬の一種は、化学療法後に投与された患者さんの25%で腫瘍の大幅な退縮をもたらすことが実証されています。3つの免疫療法薬-ペンブロリズマブ、アテゾリズマブ、ニボルマブは、特定の非小細胞肺がんの治療薬として承認されています。さらに、複数の組織が免疫療法研究に資金を提供しており、市場拡大を後押しすると予想されます。例えば、2022年、がんのための革新的な免疫療法薬を作るために、Parker Institute for Cancer Immunotherapyは、科学者やビジネスのパイオニアと協力しました。したがって、免疫療法への投資と採用の増加は、世界の肺がん治療薬市場の需要を促進しています。

がん治療別副作用

肺がんは慢性疾患であり、治療も長期にわたります。これらの治療は、薬剤に大量かつ長時間さらされるため、人体に影響を及ぼします。がん治療薬に関連する一般的な副作用には、呼吸障害、疲労、感染症、出血、貧血、胃腸障害（吐き気、嘔吐、下痢、便秘）、外見の変化、抜け毛などがあります。例えば、化学療法はがん細胞を攻撃しますが、毛根、血液、口、消化器系などの健康な細胞にも影響を及ぼします。さらに、副作用は人によって異なり、がんの治療に使用される量も異なります。したがって、がん治療の副作用は、市場の成長を妨げると予測されています。

最近の開発状況

  • 2019年3月、AdoRx Treatments Limitedは、全く新しい革新的な肺がん治療薬の創出に向けて、Johnson &Johnson Innovation LLCおよびLung Cancer Initiative at Johnson &Johnson（LCI）との戦略的提携を発表しました。

利用可能なカスタマイズ

与えられた市場データをもとに、TechSci Researchは企業の特定のニーズに応じてカスタマイズを提供します。本レポートでは、以下のカスタマイズが可能です：

会社情報

  • 追加市場プレイヤー（最大5社）の詳細分析およびプロファイリング。

目次

第1章 サービス概要

  • 市場の定義
  • 市場の範囲
    • 対象市場
    • 研究対象年
    • 主な市場セグメンテーション

第2章 調査手法

  • 調査目的
  • ベースライン調査手法
  • 主要産業パートナー
  • 主な協会と二次情報
  • 調査手法
  • データの三角測量と検証
  • 前提条件と限界

第3章 エグゼクティブサマリー

  • 市場概要
  • 主要市場セグメンテーションの概要
  • 主要市場プレイヤーの概要
  • 主要地域/国の概要
  • 市場促進要因・課題・動向の概要

第4章 VOC (顧客の声)

第5章 肺がん治療薬の世界市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • がん細胞タイプ別（非小細胞肺がん（NSCLC）、小細胞肺がん（SCLC））
    • 治療法別（化学療法、放射線療法、免疫療法、標的療法、その他の治療法）
    • 地域別
    • 企業別（2022年）
  • マーケットマップ
    • がん細胞タイプ別
    • トリートメント別

第6章 北米肺がん治療薬市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • がん細胞タイプ別（非小細胞肺がん（NSCLC）、小細胞肺がん（SCLC）
    • 治療法別（化学療法、放射線療法、免疫療法、標的療法、その他の治療法）
    • 国別
  • 北米の場合：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州肺がん治療薬市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • がん細胞タイプ別（非小細胞肺がん（NSCLC）、小細胞肺がん（SCLC）
    • 治療法別（化学療法、放射線療法、免疫療法、標的療法、その他の治療法）
    • 国別
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域の肺がん治療薬市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • がん細胞タイプ別（非小細胞肺がん（NSCLC）、小細胞肺がん（SCLC）
    • 治療法別（化学療法、放射線療法、免疫療法、標的療法、その他の治療法）
    • 国別
  • アジア太平洋地域の：国別分析
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア

第9章 南米肺がん治療薬市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • がん細胞タイプ別（非小細胞肺がん（NSCLC）、小細胞肺がん（SCLC）
    • 治療法別（化学療法、放射線療法、免疫療法、標的療法、その他の治療法）
    • 国別
  • 南米：：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカ肺がん治療薬市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • がん細胞タイプ別（非小細胞肺がん（NSCLC）、小細胞肺がん（SCLC）
    • 治療法別（化学療法、放射線療法、免疫療法、標的療法、その他の治療法）
    • 国別
  • MEA：国別分析
    • UAE肺がん治療薬
    • サウジアラビア肺がん治療薬
    • 南アフリカ肺がん治療薬
    • トルコ肺がん治療薬
    • エジプト肺がん治療薬

第11章 市場力学

  • 促進要因
    • 肺がんの有病率の増加
    • タバコを吸う人の増加
    • 免疫療法の需要増
  • 課題すること
    • 高額ながん治療費
    • 医薬品の副作用について
    • 熟練労働者の不足

第12章 市場の動向と開拓

  • 製品発表会
  • M&A（合併・買収
  • 技術的な進歩

第13章 臨床試験分析

第14章 肺がん治療薬の世界市場：SWOT分析

第15章 競合情勢

  • 事業概要提供製品最近の発展財務状況（上場企業の場合）主要担当者SWOT分析
    • AstraZeneca Plc
    • Boehringer Ingelheim International GmbH.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co
    • Pfizer Inc.
    • Allergan Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Abbvie, Inc.
    • Johnson & Johnson
    • Amgen Inc.
    • Novartis AG

第16章 戦略的な提言

目次
Product Code: 14700

The global lung cancer therapeutics market is projected to witness impressive growth during the forecast period. The factors contributing to the growth of the market are the increasing incidence of lung cancer and sophisticated treatments associated with lung cancer.

Lung cancer therapeutics is a branch of medicine concerned with the treatment of lung cancer, which includes radiation therapy, chemotherapy, targeted therapy, immunotherapy, and others. The treatment also includes the adoption of personalized medicines to increase the rate of survival in terms of the high proliferation of cancer cells in the lungs.

The introduction of nanomedicines to treat lung cancer and regulatory approvals of medicines is expected to drive the growth of the market during the forecast period. Further, a surge in lung cancer prevalence and the dominance of chemotherapy are driving the growth of the market during the forecast period.

Increasing Prevalence of Lung Cancer

Lung cancer (both small cell and non-small cell) is the second most common cancer globally. As per the American Cancer Society's estimates for lung cancer in 2022, approximately 236,740 new cases of lung cancer (117,910 in men and 118,830 in women) were reported in the US, and about 130,180 (68,820 men and 61,360 women) people died due to lung cancer. Further, the overall chances of lung cancer prevalence in a man for a lifetime period are 1 in 15, and for women, the risk is about 1 in 17. This number includes smokers as we non-smokers.

The rise in demand for Immunotherapy

The use of medications, vaccinations, and other therapies to stimulate the immune system's natural defenses so that it can combat cancer is known as immunotherapy. One class of immunotherapy medication known as "anti-PD-1" has been demonstrated to result in significant tumor regression in 25% of patients who get it after a round of chemotherapy. Three immunotherapy drugs-pembrolizumab, atezolizumab, and nivolumab have been approved to treat certain non-small cell lung cancers. Additionally, several organizations are funding immunotherapy research, which is anticipated to boost market expansion. For instance, in 2022, to create innovative immunotherapy medicines for cancer, the Parker Institute for Cancer Immunotherapy collaborated with scientists and business pioneers. Hence, rising investment and adoption of immunotherapy are fueling the demand for the global lung cancer therapeutics market.

Side Effects of cancer treatment

Lung cancer is a chronic disease with lengthy treatments. These treatments affect the human body due to high and long exposure to drugs. Some of the common side effects related cancer curing drugs include breathing problems, fatigue, infection, bleeding, anemia, Stomach problems (nausea, vomiting, diarrhea, or constipation), changes in appearance, hair fall, and others. For instance, Chemotherapy attacks cancer cells, but it also impacts some healthy cells in the hair follicles, blood, mouth, and digestive system. Moreover, side effects vary from person to person and the dose used to treat cancer. Hence, the side effects of cancer treatment are projected to hamper the growth of the market.

Market Segmentation

The global lung cancer therapeutics market is segmented based on cancer cell type, treatment, region, and company. Based on Cancer Cell Type, the market is categorized into Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC). Based on Treatment, the market is segmented into Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, and Other Treatments.

Recent Developments

  • In March 2019, AdoRx Treatments Limited announced a strategic alliance with Johnson & Johnson Innovation LLC and the Lung Cancer Initiative at Johnson & Johnson (LCI) for the creation of brand-new, innovative lung cancer therapeutics.

Market Players

AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Merck & Co, Pfizer Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Abbvie, Inc., Johnson & Johnson, Amgen Inc., Novartis AG among others are the major players in the Global Lung Cancer Therapeutics Market.

Report Scope

In this report, the global lung cancer therapeutics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Lung Cancer Therapeutics Market, By Cancer Cell Type:

  • Non-small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer (SCLC)

Lung Cancer Therapeutics Market, By Treatment:

  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Targeted Therapy
  • Other Treatments

Lung Cancer Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lung Cancer Therapeutics Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Lung Cancer Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC))
    • 5.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
    • 5.2.3. By Region
    • 5.2.4. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Cancer Cell Type
    • 5.3.2. By Treatment

6. North America Lung Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
    • 6.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Lung Cancer Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Cancer Cell Type
        • 6.3.1.2.2. By Treatment
    • 6.3.2. Canada Lung Cancer Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Cancer Cell Type
        • 6.3.2.2.2. By Treatment
    • 6.3.3. Mexico Lung Cancer Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Cancer Cell Type
        • 6.3.3.2.2. By Treatment

7. Europe Lung Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
    • 7.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Lung Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Cancer Cell Type
        • 7.3.1.2.2. By Treatment
    • 7.3.2. Germany Lung Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Cancer Cell Type
        • 7.3.2.2.2. By Treatment
    • 7.3.3. United Kingdom Lung Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Cancer Cell Type
        • 7.3.3.2.2. By Treatment
    • 7.3.4. Italy Lung Cancer Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Cancer Cell Type
        • 7.3.4.2.2. By Treatment
    • 7.3.5. Spain Lung Cancer Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Cancer Cell Type
        • 7.3.5.2.2. By Treatment

8. Asia-Pacific Lung Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
    • 8.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Lung Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Cancer Cell Type
        • 8.3.1.2.2. By Treatment
    • 8.3.2. Japan Lung Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Cancer Cell Type
        • 8.3.2.2.2. By Treatment
    • 8.3.3. India Lung Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Cancer Cell Type
        • 8.3.3.2.2. By Treatment
    • 8.3.4. South Korea Lung Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Cancer Cell Type
        • 8.3.4.2.2. By Treatment
    • 8.3.5. Australia Lung Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Cancer Cell Type
        • 8.3.5.2.2. By Treatment

9. South America Lung Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
    • 9.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Lung Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Cancer Cell Type
        • 9.3.1.2.2. By Treatment
    • 9.3.2. Argentina Lung Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Cancer Cell Type
        • 9.3.2.2.2. By Treatment
    • 9.3.3. Colombia Lung Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Cancer Cell Type
        • 9.3.3.2.2. By Treatment

10. Middle East and Africa Lung Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
    • 10.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Lung Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Cancer Cell Type
        • 10.3.1.2.2. By Treatment
    • 10.3.2. Saudi Arabia Lung Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Cancer Cell Type
        • 10.3.2.2.2. By Treatment
    • 10.3.3. South Africa Lung Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Cancer Cell Type
        • 10.3.3.2.2. By Treatment
    • 10.3.4. Turkey Lung Cancer Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Cancer Cell Type
        • 10.3.4.2.2. By Treatment
    • 10.3.5. Egypt Lung Cancer Therapeutics Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Cancer Cell Type
        • 10.3.5.2.2. By Treatment

11. Market Dynamics

  • 11.1. Drivers
    • 11.1.1. Increasing Prevalence of Lung Cancer.
    • 11.1.2. Rise in the number of Tobacco Smokers
    • 11.1.3. Rise in demand for Immunotherapy
  • 11.2. Challenges
    • 11.2.1. High Cost of Cancer Treatment
    • 11.2.2. Side Effects of Drugs
    • 11.2.3. Lack of skilled workforce

12. Market Trends & Developments

  • 12.1. Product Launches
  • 12.2. Mergers & Acquisitions
  • 12.3. Technological Advancements

13. Clinical Trial Analysis

14. Global Lung Cancer Therapeutics Market: SWOT Analysis

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Product Offerings
  • 15.3. Recent Developments
  • 15.4. Financials (In Case of Listed Companies)
  • 15.5. Key Personnel
  • 15.6. SWOT Analysis
    • 15.6.1. AstraZeneca Plc
    • 15.6.2. Boehringer Ingelheim International GmbH.
    • 15.6.3. Bristol-Myers Squibb Company
    • 15.6.4. Eli Lilly and Company
    • 15.6.5. F. Hoffmann-La Roche Ltd.
    • 15.6.6. Merck & Co
    • 15.6.7. Pfizer Inc.
    • 15.6.8. Allergan Inc.
    • 15.6.9. Teva Pharmaceutical Industries Ltd.
    • 15.6.10. Abbvie, Inc.
    • 15.6.11. Johnson & Johnson
    • 15.6.12. Amgen Inc.
    • 15.6.13. Novartis AG

16. Strategic Recommendations